Allogene Therapeutics
Dr. Jae Park is an Associate Attending Physician in the Division of Hematologic Oncology, Leukemia Service, a Director of the Adult Acute Lymphoblastic Leukemia Program, and the Acting Chief of Cellular Therapeutics Service at Memorial Sloan Kettering Cancer Center in New York, New York. Dr. Park received his medical degree from the Johns Hopkins School of Medicine and completed an internal medicine residency at Massachusetts General Hospital and a hematology/oncology fellowship at Memorial Sloan Kettering Cancer Center. Dr. Park has written numerous peer-reviewed articles appearing in the New England Journal of Medicine, Science Translational Medicine, Blood, Cancer Discovery, and Journal of Clinical Oncology. His research – which focuses on translating and establishing novel targeted and immunotherapies for patients with hematologic malignancies – has been recognized and funded by The American Society of Hematology, The American Association for Cancer Research, The American Society of Clinical Oncology, The Leukemia and Lymphoma Society, The Geoffrey Beene Research Foundation, and The National Comprehensive Cancer Network. Widely recognized as one of the world's experts in cell therapies, Dr. Park is the leading principal investigator of several clinical trials in patients with non-Hodgkin lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.
This person is not in the org chart
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.